TABLE 1.

Comparison of immunological and virological parameters between subtype B and non-subtype B infections

Characteristic	Value(s) for participants infected with:		P value
	Subtype B (n = 25)	Non-subtype B (n = 5)
Baseline
Median (IQR) plasma viral load (no. of log10 copies/ml)	4.2 (3.7–4.8)	4.8 (3.6–5.0)	0.8
Median (IQR) CD4+ T-cell count (no. of cells/mm3)	440 (360–685)	630 (345–750)	0.7
Median (IQR) proviral DNA load (no. of log10 copies/106 CD4+ T cells)	3.4 (3.1–3.9)	2.8 (2.1–3.2)	0.01
Median (IQR) no. of replication-competent HIV copies (no. of log10 IUPMa /106 CD4+ T cells)	1.2 (0.9–2.0)	1.2 (0.2–1.9)	0.7
% MAA+b for very early cARTc	80	20	0.6
Median (IQR) granzyme B response (no. of spot-forming cells/106 PBMCd )	2,710 (946–3,930)	3,863 (2,380–8,860)	0.095
Median (IQR) maximal normalized Nef-mediated HLA downregulation (% function)	88 (73–95)	54 (45–72)	0.006
Maximal normalized Nef-mediated CD4 downregulation (% function)	99 (96–101)	97 (90–99)	0.1
Post-cART (wk 48)
Median (IQR) proviral DNA load (no. of log10 copies/106 CD4+ T cells)	2.5 (2.3–2.9)	1.7 (1.0–2.1)	0.0008
Median (IQR) no. of replication-competent HIV copies (log10 IUPM/106 CD4+ T cells)	−0.3 (−0.6 to 0.2)	−0.8 (−1.1 to −0.5)	0.03

^aIUPM, infectious units per million CD4⁺ T cells.

^bMAA⁺, multiassay algorithm positive (participants who started cART within an estimated 141 days after infection).

^ccART, combination antiretroviral therapy.

^dPBMC, peripheral blood mononuclear cells.